Sign up USA
Proactive Investors - Run By Investors For Investors

NetScientific brings in ex-Novartis man to deliver diagnostics portfolio

Diagnostics executive and ex- Novartis man Gene Walther has been appointed the head of NetScientific's (LON:NSCI) portfolio firm Vortex BioSciences - as the biomedical firm continues to restructure towards a sector franchise model.
NetScientific brings in ex-Novartis man to deliver diagnostics portfolio
Vortex BioSciences is developing a bench top instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers

Diagnostics executive and ex- Novartis man Gene Walther has been appointed the head of NetScientific's (LON:NSCI) portfolio firm  Vortex BioSciences - as the biomedical firm continues to restructure towards a sector franchise model.

Walther also becomes head of the group's diagnostic franchise.

Vortex BioSciences is developing a bench top instrument, which runs a simplified, high-speed blood test for a wide range of metastatic cancers.

The firm is currently run by interim chief executive Dr Michael Boyce-Jacino who is leaving the group and board at the end of December this year.

NetScientific's group chief executive Francois Martelet said on Monday: "Gene's experience and calibre will further strengthen our team to help drive our commercialisation programme for Vortex and our entire diagnostics franchise, as part of our planned management restructure."

Walther will join on  January 4 to accelerate the development and delivery of Vortex's laboratory systems and spearhead the co-ordination and delivery of  its  diagnostics portfolio.

Among his previous roles, he served as the executive chairman of GenturaDx where he led this start-up diagnostics firm through product and company development leading to a strategic acquisition by Luminex.

He also spent 11 years at Novartis as president and global Head of diagnostics.

Walther said today: "Vortex has the potential to revolutionise the way cancer is diagnosed, monitored and treated. I'm excited to be able to play a role in the commercialisation of this technology."

Giles_55af4ddca6481.jpg


Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

Related Articles

Knee surgery
July 13 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
A llama
September 13 2016
Proactive Investors looks at Abzena, a biotech firm that engineers antibodies from animals in order to boost the effectiveness of cancer-fighting drugs.
CancerHeadline.jpg
February 24 2016
"We are swiftly moving towards our goal of becoming a clinical-stage development company," said CEO, Dr Tim Mitchell
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC